Quantcast

Latest Isis Pharmaceuticals Inc. Stories

2014-08-28 08:27:42

CARLSBAD, Calif., Aug. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIII(Rx) in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. The Phase 3 study of ISIS-APOCIII(Rx) is a randomized, double-blind, placebo-controlled, six month study in approximately...

2014-08-15 08:24:22

CARLSBAD, Calif., Aug. 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO The open-label extension study of ISIS-SMN(Rx) is offered to those children with SMA who have completed dosing in Isis'...

2014-08-04 08:28:12

- $40 million in milestone payments from partners drives improved quarterly financial performance CARLSBAD, Calif., Aug. 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,000 for the same periods in 2013. Isis' pro forma operating income in the second...

2014-08-01 08:25:54

-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which time Isis will earn an $18 million milestone payment from its...

2014-07-28 08:28:42

CARLSBAD, Calif., July 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2014 Financial Results and Highlights Conference Call When: Monday, August 4 at 10:30 a.m. ET /7:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above....

2014-07-17 08:28:35

CARLSBAD, Calif., July 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)(Rx) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)(Rx) is designed to reduce Lp(a) by inhibiting the production of...

2014-07-16 08:27:14

CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare...

2014-07-02 08:26:15

CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline. We look forward to continuing to advance...

2014-06-24 08:29:49

CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and...

2014-06-17 08:28:25

CARLSBAD, Calif., June 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis'...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related